In another study, exposure of treatment naïve EGFR-mutant PC-9 NSCLC cells to conditioned media of erlotinib-treated cells also enhanced drug resistance in a STAT3-dependent manner [35]. Here, STAT3 is linked to non-small cell lung carcinoma.